Target Price | $12.13 |
Price | $4.06 |
Potential |
198.65%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Ironwood Pharmaceuticals 2025 .
The average Ironwood Pharmaceuticals target price is $12.13.
This is
198.65%
register free of charge
$23.00
466.50%
register free of charge
$4.00
1.48%
register free of charge
|
|
A rating was issued by 8 analysts: 6 Analysts recommend Ironwood Pharmaceuticals to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ironwood Pharmaceuticals stock has an average upside potential 2025 of
198.65%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 442.74 | 356.90 |
7.83% | 19.39% | |
EBITDA Margin | 47.57% | 22.67% |
22.42% | 52.34% | |
Net Margin | -232.72% | 11.56% |
736.36% | 104.97% |
8 Analysts have issued a sales forecast Ironwood Pharmaceuticals 2024 . The average Ironwood Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Ironwood Pharmaceuticals EBITDA forecast 2024. The average Ironwood Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Ironwood Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Ironwood Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -6.45 | 0.26 |
786.17% | 104.03% | |
P/E | 15.72 | |
EV/Sales | 3.32 |
6 Analysts have issued a Ironwood Pharmaceuticals forecast for earnings per share. The average Ironwood Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Ironwood Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Ironwood Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.